The efficacy of first and second immunotherapy exposure in patients with recurrent or metastatic cervical cancer
The baseline CRP levels in serum was an independent factor for PFS and OS of R/M CC patients treated with immunotherapy, and previous antiangiogenic therapy was associated with poor OS. Patients still show response to immunotherapy rechallenge and combined treatment with bevacizumab or candonilimab showed higher response rate than anti-PD-1 after immunotherapy failure.
Authors
- Jundong Li (ORCID: https://orcid.org/0000-0002-1878-817X)
- Baoyue Pan (ORCID: https://orcid.org/0000-0001-5922-7136)
- Chunyan Lan
- Mingxiu Ju (ORCID: https://orcid.org/0009-0008-1617-8889)
- Siyu Chen (ORCID: https://orcid.org/0000-0002-3809-1062)
- Min Zheng (ORCID: https://orcid.org/0000-0003-4565-844X)
- Yun Zhou (ORCID: https://orcid.org/0000-0002-6255-301X)
- Huiling Xiang (ORCID: https://orcid.org/0000-0001-5734-4080)
- Yongwen Huang
- Jieping Chen (ORCID: https://orcid.org/0000-0003-2834-2961)
- Shije Xu
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1002/cam4.70204
- Citations
- 6
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.50
Funders
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province